Pharmaceutical Pricing and Reimbursement Information (PPRI): a European Union project


Background: In the European Member States, the systems for pharmaceutical pricing and reimbursement differ significantly. Amongst the administration and policy-makers at both national and European levels there is a lot of interest in the different pharmaceutical systems of the Member States as a means of learning from their experiences in pricing and reimbursement.

Objectives: The general objective of the PPRI–Project – started in April 2005 - is to develop a network of authorities and institutions in order to improve information and knowledge on the pharmaceutical systems in the enlarged European Union. This network should facilitate a regular exchange of information and allow a process of learning from each other.

Project description: The PPRI project team consists of the main partner (ÖBIG), an associated partner (WHOEURO) and a network of partners and observers which represent national stakeholders from almost all EU Member States and a number of international stakeholders. The information on pharmaceutical pricing and reimbursement will be collected and summarised in country reports (“Pharma Profiles”) which follow a homogenous structure. The individual country’s information will be analysed and compared on the basis of a set of indicators (benchmarks).

Deliverables:The main deliverables of the project are:

 • Pharma Profiles, • a benchmarking report, in which pharmaceutical pricing and reimbursement in the Member States is compared,

• a website containing information on the project and on pricing and reimbursement in the Member States, and

 • a conference at the end of the project during which the study results will be disseminated.


Pharmaceuticals; pricing; reimbursement; Europe; PPRI

Full Text:






  • There are currently no refbacks.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it (Read more).